Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 7/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4007580 | 1.00 | VEGFA (0.47) | VEGFAEGLN1FPR2RAB9AHTT | |
| SCHEMBL4013822 | 0.96 | VEGFA (0.43) | VEGFAEGLN1FPR2RAB9AHTT | |
| SCHEMBL4008772 | 0.90 | KDM1A (0.40) | VEGFAEGLN1FPR2 | |
| SCHEMBL5567270 | 0.86 | VEGFA (0.47) | VEGFAEGLN1RAB9AHTTCCR2 | |
| SCHEMBL7095007 | 0.85 | VEGFA (0.61) | VEGFAEGLN1FPR2RAB9AHTT | |
| SCHEMBL5567663 | 0.81 | ALDH1A1 (0.50) | VEGFAEGLN1CCR2ALDH1A1KDM4E | |
| SCHEMBL5989656 | 0.80 | POLB (0.39) | VEGFAEGLN1FPR2RAB9AHDAC1 | |
| SCHEMBL3455133 | 0.78 | VEGFA (0.46) | VEGFAEGLN1RAB9AHTTCCR2 | |
| SCHEMBL14272843 | 0.78 | HDAC1 (0.47) | VEGFAEGLN1HDAC1HDAC8HDAC6 | |
| SCHEMBL1347170 | 0.77 | HTR2C (0.51) | VEGFAEGLN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569562-B2 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | claimed |
| EP-1838701-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2007-10-03 | — | — | EP | claimed |
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | claimed |
| WO-2006078753-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | claimed |
| US-7569562-B2 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1838701-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006078753-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | SULT2A1, PSEN1, PSEN2 | VEGFA 4674/4885EGLN1 775/4885FPR2 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.